Recombinant erythropoietin receptor protein
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 3, 1995
Issued Date -
N/A
app pub date -
Jun 10, 1993
filing date -
Feb 3, 1989
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention described encompasses an isolated DNA sequence encoding all or a portion thereof of a cell surface receptor murine and human erythropoietin (hereinafter EPO-R), along with the isolated polypeptide expressed by the DNA sequence (i.e., isolated EPO-R). The invention also encompasses host cells containing the above-described DNA sequence, preferably, host cells which express the polypeptide encoded by the DNA sequence (EPO-R) at a significantly higher level than that produced by normal red blood cell precursors. The invention further encompasses DNA sequences encoding secreted forms of the human EPO-R and polypeptides corresponding thereto. The EPO-receptor in all of the disclosed forms can be used as models for designing drugs or in pharmaceutical compositions for treating anemias.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully